Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Common Equity (2016 - 2025)

Lexaria Bioscience's Common Equity history spans 11 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 47.7% year-over-year to $4.9 million; the TTM value through Nov 2025 reached $4.9 million, down 47.7%, while the annual FY2025 figure was $2.6 million, 66.02% down from the prior year.
  • Common Equity for Q4 2025 was $4.9 million at Lexaria Bioscience, up from $2.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $13.1 million in Q3 2021 and bottomed at $2.6 million in Q3 2025.
  • The 5-year median for Common Equity is $7.2 million (2022), against an average of $7.4 million.
  • The largest annual shift saw Common Equity surged 529.79% in 2021 before it plummeted 66.02% in 2025.
  • A 5-year view of Common Equity shows it stood at $11.5 million in 2021, then crashed by 48.28% to $5.9 million in 2022, then plummeted by 43.14% to $3.4 million in 2023, then surged by 178.53% to $9.4 million in 2024, then plummeted by 47.7% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Common Equity are $4.9 million (Q4 2025), $2.6 million (Q3 2025), and $5.6 million (Q2 2025).